ADXN

Addex Therapeutics Ltd is a pioneering clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland, focused on the discovery and development of innovative small molecule therapeutics for central nervous system (CNS) disorders. Leveraging its proprietary allosteric modulation technology platform, the company is advancing a promising pipeline designed to fulfill critical unmet medical needs in CNS health. With a steadfast commitment to regulatory approval and commercialization of its novel therapies, Addex is positioned to make a meaningful impact on the biopharmaceutical landscape and enhance treatment options for patients suffering from CNS conditions.